Market Place
Sourcing Support
Vico Therapeutics Announces Positive VO659 Data In Huntington`s Disease
13 Sep 2024 //
PR NEWSWIRE
Seroba and Kurma Partners Announce Complementary Series B Funding for Vico
24 Jun 2024 //
BUSINESSWIRE
Vico Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659
03 Apr 2023 //
PR NEWSWIRE
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659
29 Jul 2021 //
PRNEWSWIRE
Vico Therapeutics’ antisense oligonucleotide therapy, VO659
11 Feb 2021 //
PHARMABIZ
EC Grants Orphan Drug Designation to Vico Therapeutics’ Oligonucleotide SCA
11 Feb 2021 //
PHARMTECH
European Commission grants Vico Therapeutics Orphan Drug Designation for VO659
10 Feb 2021 //
PRNEWSWIRE
Dutch Vico strengthens leadership team with the appointment of Rupert
01 Oct 2020 //
PRNEWSWIRE
European neuro biotech Vico nabs Bayer alum as CMO
01 Oct 2020 //
FIERCE BIOTEC
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.